康泰生物(300601.SZ):四價流感病毒裂解疫苗開啟Ⅰ期臨牀試驗併成功完成首例受試者入組
格隆匯2月13日丨康泰生物(300601.SZ)公佈,公司研發的四價流感病毒裂解疫苗已完成Ⅰ期臨牀試驗準備工作,開啟Ⅰ期臨牀試驗,並於近日成功完成首例受試者入組。
四價流感病毒裂解疫苗適用於3歲及以上人羣,可刺激機體產生抗流感病毒的免疫力,用於預防疫苗相關型別的流感病毒引起的流行性感冒。流行性感冒(也稱流感)是由流感病毒引起的急性呼吸道傳染病,接種流感疫苗是預防流感疾病及流感大爆發最有效和最經濟的措施。
經查詢國家藥品監督管理局網站,目前國內已上市的四價流感病毒裂解疫苗的廠家包括華蘭生物疫苗股份有限公司、江蘇金迪克生物技術股份有限公司、長春生物製品研究所有限責任公司、北京科興生物製品有限公司、武漢生物製品研究所有限責任公司和上海生物製品研究所有限責任公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.